Implant Sciences Hires Investor Relations Firm

Implant Sciences Corporation (AMEX: IMX), a supplier of sensors, systems and services for the homeland security and microelectronics industries, today announced it has retained Mozes Communications, LLC for strategic investor relations counsel. Mozes Communications, LLC is a boutique investor relations firm, specializing in small-cap, technology-oriented companies. "We believe it is important to effectively communicate Implant Sciences’ strategy, milestones, and successes with the investment community as we execute on our transformation plan and position the company for future growth,” said Phillip C. Thomas, CEO and President. "We are pleased that Mozes Communications has joined our team to help increase investor awareness and maintain effective communications with our stockholders. As we achieve our business and financial objectives, we believe Mozes Communications can help enhance our investor communications activities and broaden our investor following.” About Implant Sciences Implant Sciences develops, manufactures and sells sophisticated sensors and systems, as well as provides services for the Security, Safety and Defense (SS&D) and microelectronics industries. The Company has developed proprietary technologies used in its commercial portable and bench-top explosive trace detection (ETD) systems, which ship to a growing number of locations domestically and internationally. The Company has also developed and acquired technologies using ion implantation and thin film coatings for microelectronics and other applications. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com. Safe Harbor Statement This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements are subject to risks and uncertainties, including but not limited to, difficulties in implementing its transformation plan, the risk that its transformation plan may not result in future growth, the Company’s ability to achieve its business and financial objectives, and the risk that those achievements and investor communications do not result in a broadened investor following. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information, you are encouraged to review Implant Sciences’ filings with the Securities and Exchange Commission, including its Forms 10-K, 10-Q and 8-K, which describe risk factors that could have adverse effect on its results. The Company assumes no obligation to update the information contained in this press release.